Controlled release dosage form comprising different cellulose ethers

• US 4,871,548 A
• Filed: 04/17/1987
• Issued: 10/03/1989
• Est. Priority Date: 04/06/1987
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Magruder, Judy A., Edgren, David E., Bhatti, Gurdish K.
• Primary Examiner(s): Page, Thurman K.
• Application Number:
  US07/039,405
• Time in Patent Office: 900 Days
• Field of Search: 424/468, 424/469, 424/464, 424/470, 424/499, 424/488, 424/484
• US Class Current: 424/488
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer

Abstract

A dosage form is disclosed comprising a low number average molecular weight hydroxypropylmethylcellulose, a high number average molecular weight hydroxypropylmethylcellulose, and a beneficial drug.

Claims

1. A dosage form for delivering a beneficial drug to an environment of use, which dosage form comprises:

a matrix adapted for entrance into the environment of use, said matrix comprising from 30 to 99.9% of a cellulosic ether formulation, which formulation comprises from 10 to 99% of at least one hydroxypropylmethylcellulose comprising a high number average molecular weight of from 30,000 to 350,000, from 5 to 80% of at least one hydroxypropylmethylcellulose comprising a low number average molecular weight of from 9,000 to 30,000, from 2 to 30% of a hydroxypropylcellulose comprising a hydroxypropoxy content of 7 to 16%, and a dosage amount of the beneficial drug.

2. The dosage form for delivering the beneficial drug to the environment of use, according to claim 1, wherein the environment of use is the fluidic gastrointestinal tract of a warm-blooded animal.

3. The dosage form for delivering the beneficial drug to the environment of use, according to claim 1, wherein the environmemt of use is the human stomach.